JH
Jake Y Henry
Garvan Institute of Medical Research, University College London, Western Sydney University, St George's Hospital
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · T-cell and B-cell Immunology · Immunotherapy and Immune Responses
0000-0003-0435-3308
Employment
-
Garvan Institute of Medical Research Research Officer2019 - Present
-
University College London Research Technician2010 - 2019
-
St George's Hospital Research Assistant2006 - 2010
Education
-
University College London PhD / Cancer Immunology2013 - 2019
- 2000 - 2003
Projects & Funding
Projects & funding information is unavailable.
Publications (23)
- Energy-guided combinatorial co-optimization of antibody affinity and stability Save
- Human genomic DNA is widely interspersed with i-motif structures Save
- Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients Save
- Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients Save
- Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability Save
- Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. Save
- CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Save
- Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Save
- The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Save
- Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma. Save
- Neoantigen-directed immune escape in lung cancer evolution. Save
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Save
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Save
- The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells. Save
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Save
- TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Save
- CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. Save
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. Save
- Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Save
- Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Save